Mia E. Lussier

Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol

OBJECTIVE: This article describes pharmacology, pharmacokinetics, safety, and efficacy data of enlicitide, the first Food and Drug Administration (FDA)-approved oral proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). DATA SOURCES: PubMed, Embase, Web of Science, an...